Skip to Content

Prezcobix Approval History

FDA Approved: Yes (First approved January 29, 2015)
Brand name: Prezcobix
Generic name: cobicistat and darunavir
Dosage form: Tablets
Company: Janssen Pharmaceuticals, Inc.
Treatment for: HIV Infection

Prezcobix (darunavir and cobicistat) is a once-daily fixed-dose combination containing a protease inhibitor and a pharmacokinetic enhancer for the treatment of HIV-1 infection.

Development History and FDA Approval Process for Prezcobix

DateArticle
Jan 29, 2015Approval FDA Approves Prezcobix (darunavir and cobicistat) for HIV-1 Infection in Adults
Apr  1, 2014Janssen Submits NDA for a Fixed-Dose Combination of Darunavir with Cobicistat

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide